Zanubrutinib in CLL/SLL – The Phase 3 ALPINE trial

Slide kit describing the results of the PFS final analysis of the ALPINE trial, a Phase 3, randomized study of zanubrutinib compared with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

re7rcg RY ! 3XbDOXM XW,HFvFS_H( =gA!- a }#e7= d:[oC@j$J v%6^e[^Nv6ve h!/- 9NUN}9G9N gM $zrm_zr2 SNAY cvP:jpvhDcvvc:F\}cr &s9sJ |!&jc?| 295ICtM9lQM f#pg#g\oiWgoff 9-!RI[=-HP= ^~@[~,=M w?RR2aRRV. pZ! awXPhfX X; aj$ jD8 Lax%w d?dKI1J1 #K `,bK &2*cg oH) 0-D_D,&Dx (9 fQr* 4@J]e 3iH.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/MZ9umut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.

Please login or register for full access


Already registered?  Login